Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
1,33 USD | -4,32 % | -1,48 % | -18,40 % |
21/03 | Transcript : InflaRx N.V. - Special Call | |
21/03 | InflaRx N.V. publie ses résultats pour l'exercice clos le 31 décembre 2023 | CI |
Métier
Nombre d'employés: 62
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Monoclonal Antibodies
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 01/12/07 |
Niels Riedemann
FOU | Founder | 51 | 01/12/07 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 01/10/20 |
Camilla Chong
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/07/23 |
Daniel Vetter
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/22 |
Maria Habel
CTO | Chief Tech/Sci/R&D Officer | 41 | 01/01/08 |
Bruce P. Burnett
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/20 |
Jan Medina
IRC | Investor Relations Contact | - | 22/02 |
Nicole Bertsch
HRO | Human Resources Officer | - | 01/03/21 |
Christian Schmid
LAW | General Counsel | - | 01/01/21 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 01/12/07 |
Niels Riedemann
FOU | Founder | 51 | 01/12/07 |
Renfeng Guo
FOU | Founder | 53 | 01/12/07 |
Hege Hellstrom
BRD | Director/Board Member | 59 | 01/04/23 |
Richard Brudnick
BRD | Director/Board Member | 67 | 14/02/19 |
Anthony Gibney
BRD | Director/Board Member | 53 | 06/02/18 |
Mark Kubler
BRD | Director/Board Member | 49 | 01/01/15 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 58 883 272 | 54 560 784 ( 92,66 %) | 0 | 92,66 % |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. |
Biotechnology
|
Secteur
Ventes par région
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
-18,40 % | 81,85 M | |
-2,31 % | 103 Md | |
+0,56 % | 95,71 Md | |
+1,69 % | 22,02 Md | |
-17,37 % | 20,9 Md | |
-9,30 % | 17,85 Md | |
-41,01 % | 16,21 Md | |
-14,85 % | 15,52 Md | |
+3,21 % | 13,86 Md | |
+33,54 % | 12,04 Md |
- Bourse
- Actions
- Action IFRX
- Société InflaRx N.V.